

Dr. T. Yukawa - Quality Quest Australia Dr. M. Venning - Valutech

Overview

- Current and Predicted Market
- Drivers of the Industry
- Sectors
- Comparison with Australia
- Opportunities for Australia
- Approaches to the Japanese Market
- Case Study Diagnostics

Background

- 1999 2001 Bureaucratic Reform
- 2002 Government Decision to Promote Biotechnology
 - Biotechnology Strategy Council
 - Tax incentives to stimulate R&D
 - Large clinical trials network to be established
 - Public funds for medical start ups
 - Academics to work with industry

JAPANESE BIOTECH MARKET 2001/2010

[Source: METI 2002 Units: AUD billion]

SECTOR	2001	2010	CAGR
Human Health	7.00	109	36%
Agri-Food	4.77	82	37%
Bioprocess	3.17	47	35%
Environment & Resources	0.04	8	80%
Biotool	1.82	40	41%
Bioinformatics	0.38	29	62%
Services & Other	0.34	10	46%
Total	17.47	325	38%


JAPANESE BIOTECH MARKET Sectors

- Almost entirely internal market with few exports
- Human Health(40%) EPO, C-GSF, MAbs, GH, Insulin
- AgriFood (27%) maize, functional food, special health foods
- Bioprocess (18%) enzymes for food & detergents
- Biotools (10%) biosensors, analytical equipment
- Bioinformatics (2%) complete cDNA cloning
- Environment bioremediation
- Services (2%) -

JAPANESE BIOTECH MARKET Drivers

- FY2001 GERD AUD215 billion
- 3.3% GDP
- 69% business
- Breakdown
 - Basic 15%
 - Applied 23%
 - Dev't 62%
- Life Sciences 10% approx.

R&D Expenditure



JAPANESE BIOTECH MARKET Drivers - Government

National Government Ministries

- Ministry of Economy, Trade and Industry -METI
- Ministry of Education, Culture, Sports,
 Science and Technology MEXT
- Ministry of Agriculture, Forestry and Fisheries - MAFF
- Ministry of Health, Labour and Welfare -MHLW

JAPANESE BIOTECH MARKET Drivers - Government

- METI (~AUD 350M)
 - Links to broad industry sectors
 - Research institutions such as NIAIST and NIBHT
 - Links to Japan Bioindustry Association (190 companies) and Research Association for Biotechnology for priorities
- MEXT (~AUD 900M)
 - Regulation of university sector
 - Research institutions such as RIKEN as well as university research groups and associations
 - 32 Technology Licensing Organisations

JAPANESE BIOTECH MARKET Drivers - Government


- MAFF (~AUD 300M)
 - Regulation of all agriculture activities
 - Research institutes
 - Links to Japan Society for Techno-innovation of Agriculture, Forestry and Fisheries (160 companies)
- MHLW (over AUD 1,600M)
 - Regulation of all health matters including pharma, medical devices and diagnostics
 - Links to Japan Health Sciences Foundation (154 companies)

JAPANESE BIOTECH MARKET Drivers - Local Government

- Promote industrial clusters
- Promote public private partnerships
- Fund regional institutes with industry
- Main focus Tokyo,Osaka and Hokkaido




JAPANESE BIOTECH MARKET Drivers - Industry



Pharmaceuticals

- 50% controlled by domestic companies
- 20% by Japanese companies under foreign licence
- Increasingly looking to foreign markets with major companies having >40% of sales O/S
- Establishing O/S R&D and marketing operations
- Commercial incentive for new products


AUD 480 Billion



Medical Devices

- 57% sourced domestically
- Major import demand for biomedical transplantation devices and surgical equipment
- Easier access to market from 2005


AUD 200 Billion



In Vitro Diagnostics

- Thin margins
- Large distribution costs
- 50% of immunoassay products imported but other products almost entirely local
- Local producers of instrumentation strong

AUD 30 Billion



Agriculture

- Relatively underexploited due to highly protected nature
- Strong emphasis on seed industry with focus on rice and then vegetables
- Major corporate players are from pesticide, seed, beverage and brewing industries as well as agricultural cooperatives

Food & BioProcess

- Strong highly competitive industry reliant on imported material
- Long history of fermentation to produce food with adaptation to other industries rather than extension in existing industries
- New category Special Health Foods focus of considerable market attention

Biotools

- Area of significant government support
- Building on strong electronics and laboratory equipment base and relying on increase in local demand
- Interest in nano-medical device development


Bioinformatics

- Relatively under-developed and hence focus of Government push
- RIKEN's Genomic Sciences Centre
- Helix Research Institute Inc. funded by industry and government
- Significant strategic patent approach


Environment

- Market over AUD 300 billion and growing at 3.7%pa
- Expecting rapid growth in
 - Soil and water remediation
 - Pollution prevention services
 - Energy saving and management
- Industry highly competitive particularly in industrial pollution control but opportunities in soil and water remediation and associated services
- Major sector is wastewater treatment


Comparison with Australia




Comparison with Australia




Comparison of Start Ups - Sectors




Opportunities





Opportunities



Australia Japan Activities Products/Equipment

Equipment

- Corbett Research
- Vita Medical
- Vision Biosystems
- Axon/Molecular Devices
- Cryologic
- Riancorp
- Optiscan
- ResMed
- Compumedics

Biologicals

- CSL/JRH
- Moregate
- SC Botanicals
- Herbworx
- Thermo Trace
- GR Davis

Other

- Genetic Solutions
- Ozgene
- Mimotopes

Australia Japan Activities Regulated Products

Diagnostics

- Life Diagnostics
- PanBio
- Biota
- Cellestis

Other

- Cochlear
- BioProperties
- Atcor Medical

Australia Japan Activities Technology Licensing

- Chemgenex Pharmaceuticals
- Byron Australia
- Mayne Pharma
- Food Science Australia
- Optiscan
- Virotec
- Environmental Solutions
- SciGen

Australia Japan Activities R&D Collaboration

- AMRAD
- Cerylid Biosciences
- RMIT
- St. Vincent's Institute Medical Research
- Animal Reproduction Co.
- Centre for Animal Biotechnology
- Children's Medical Research Institute

Australia Japan Activities Joint Ventures

- Stem Cell Sciences
- Proteome Systems
- Bioproperties Australia
- Waste Technologies Australia

Australia Japan Activities Investments

- Florigene (Suntory)
- Bioclone (Hitachi)
- Biocontrol (Shinetsu Chemical)
- Cerylid Biosciences (JAFCO/Starfish)
- Optiscan (Asahi Optical)
- Shimadzu



- Neurosciences Victoria (Nissho Iwai)
- Institute for Molecular Bioscience (Itochu)
- Food Sciences Australia (Itochu)
- Proteome Systems (Itochu and Shimadzu)

Approaching the Market

- Homework (low \$)
 - Gather information on target market and industry
 - Critically evaluate appropriateness of offering (why would they be interested?)
- Strategy (low \$)
 - Targeting the entry point creating opportunities
 - Trading Co > Importer > Marketer > Distributor >
 Specialist > Consumer

Approaching the Market

- Creating Opportunities (low to mod. \$)
 - Trade Fairs oriented to established products
 - International Conferences low success rate hit or miss - like with like
 - Government support
 - Austrade more active can be counterproductive
 - JETRO more passive first step only
 - Global Venture Forum high focus but requires preparation
 - Academic linkages
 - Provides introductions only
 - Opens and closes doors limitations

Approaching the Market Linkages

Trading Companies

- Provides ready access
- Route to market must be clear, rapid and provide good return
- Additional intermediary and margin

Investment Companies

- Good potential
- Variable track record

Approaching the Market Linkages

- Company Matching/ Individuals
 - Selection
 - Terms of arrangement
 - Need for continuing contribution
 - Need for parallel official and non-official chanels
 - Need for advice on interaction

Regulatory Requirements

- Pharmaceuticals, Medical Devices and Veterinary
 Medicine Pharmaceutical Affairs Law, GMP, GLP, GCP
- Foods Food Hygiene Law
- Agriculture Guideline for Release of Recombinant Plant /Organisms
- Environment Environment Law

Case of Company C

Background

- Newly established Australian company with limited financial capacity
- Novel in vitro diagnostic for detection of disease
- Some IP protection
- Japan still has high infection rate
- Japanese market is monopolized by one company
- Protocol of diagnosis is specified by special law

Objective

 Selection of partner - interested in distribution and capable to obtain an import permit of the test

Process

- Identification/Assessment of key factors
 Influential government organization in Japan
 Resistance force in Japan Monopoly company
 Likely distributors Fujirebio, Kyowa Medex, Chugai,
 Monopoly company
- Approach

Introduction through respected person/organization - JETRO, Austrade and/or personal connection

Process

- Selection of a Partner
 - Nichirei, why?
 - Terms and conditions on distribution and clinical trials
- Modification of product to meet market requirements
 - Second generation kit
- Building up working relationship
 - Generation of clinical & non-clinical data in Australia/Japan
 - Human factor, product champion

